Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

IN8bio, Inc.

INAB ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.38

▼ -1.43%

Market Cap $13.60M · Vol 1.23K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$13.60M

Micro Cap

Div Yield

N/A

EPS Growth

+74.93%

YoY

RSI (14)

80.00

Momentum

Beta

0.24

vs Market

52W High

$2.71

49.08% below

52W Low

$0.89

54.83% above

Volume

1.23K

Avg 8.10K

P/B

0.83

Price-to-book

ROE

N/A

Return on equity

Free Float

92.42%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, IN8bio, Inc. (INAB) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INAB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.43%

+21.05%

+0.00%

-4.83%

YTD

-41.03%

-42.74%

-95.45%

-99.27%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-19,440,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-73.05% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.83
P/FCF	N/A
EPS Growth	+74.93%
Outstanding Shares	9.86M

Technical Indicators

50-Day SMA	$1.14
200-Day SMA	$1.54
RSI (14)	80.00
Beta	0.24
52-Week High	$2.71
52-Week Low	$0.89

Volume Today	1.23K
Avg Daily Volume (30D)	8.10K
Relative Volume	0.15x
Volatility (10D)	34.23
Volatility (30D)	70.87
Free Float	92.42%

Analyst Consensus

BUY

Current Price $1.38

Mean Target $7.00

52W Low$0.89 52W High$2.71

Current

Target

$0.89 $2.71

Current Analyst target

+407.25% upside potential · 3 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00XX9K2G7

ISINUS45674E2081

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -4.30% ARGX.BR argenx SE -15.86% ARGX argenx SE -11.83% 2269.HK WuXi Biologics (Cayman) Inc. -4.59% GMAB Genmab A/S -1.64%

Company Profile

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.